Iversen Per Ole
Institutt for ernaeringsforskning, Universitetet i Oslo, 0316 Oslo.
Tidsskr Nor Laegeforen. 2003 Nov 20;123(22):3198-200.
It is fairly well documented that the growth and metastasis of solid tumours is accompanied by increased formation of new blood vessels emanating from a pre-existing vascular bed. Recent findings suggest that angiogenesis also takes place in haematological malignancies. These findings suggest that angiogenesis might be a potential target for therapy.
A short review is presented on the basis of literature identified on PubMed and Medline as well as our own data.
When surrogate markers are used, such as the plasma concentration of angiogenic growth factors or the density of blood vessels within the bone marrow, angiogenesis is associated with poor prognosis and treatment outcome in haematopoietic malignancy. While human treatment data are scarce, findings in animal experiments suggest that anti-angiogenesis might retard leukemogenesis.
The proliferation and dissemination of malignant blood cells seems to be related to increased angiogenesis in the bone marrow. Targeting components of the angiogenic process might offer adjunct treatment modalities in haematopoietic malignancy.
有充分文献记载，实体肿瘤的生长和转移伴随着从预先存在的血管床发出的新血管形成增加。最近的研究结果表明，血管生成也发生在血液系统恶性肿瘤中。这些发现提示血管生成可能是一个潜在的治疗靶点。
基于在PubMed和Medline上检索到的文献以及我们自己的数据进行简要综述。
当使用替代标志物时，如血管生成生长因子的血浆浓度或骨髓内血管密度，血管生成与造血系统恶性肿瘤的预后不良和治疗结果相关。虽然人类治疗数据稀少，但动物实验结果提示抗血管生成可能延缓白血病的发生。
恶性血细胞的增殖和播散似乎与骨髓中血管生成增加有关。针对血管生成过程的组成部分可能为造血系统恶性肿瘤提供辅助治疗方式。
